Evaxion Biotech A/S (NASDAQ:EVAX) vs. SAB Biotherapeutics (NASDAQ:SABS) Head-To-Head Review

SAB Biotherapeutics (NASDAQ:SABS) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current ratings for SAB Biotherapeutics and Evaxion Biotech A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	0	0	5	0	3.00
Evaxion Biotech A/S	0	0	2	0	3.00

SAB Biotherapeutics currently has a consensus target price of $12.40, indicating a potential upside of 222.92%. Evaxion Biotech A/S has a consensus target price of $55.00, indicating a potential upside of 6,011.11%. Given Evaxion Biotech A/S’s higher possible upside, analysts clearly believe Evaxion Biotech A/S is more favorable than SAB Biotherapeutics.

Volatility & Risk

SAB Biotherapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500.

Earnings & Valuation

This table compares SAB Biotherapeutics and Evaxion Biotech A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$2.24 million	15.82	-$42.19 million	N/A	N/A
Evaxion Biotech A/S	$3.30 million	1.60	-$22.12 million	($0.29)	-3.10

Evaxion Biotech A/S has higher revenue and earnings than SAB Biotherapeutics.

Profitability

This table compares SAB Biotherapeutics and Evaxion Biotech A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	-1,450.14%	-94.37%	-67.26%
Evaxion Biotech A/S	-347.83%	N/A	-79.40%

Insider & Institutional Ownership

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are owned by institutional investors. 26.5% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Evaxion Biotech A/S beats SAB Biotherapeutics on 7 of the 11 factors compared between the two stocks.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.